Drug intelligence / Profile preview

xidan

Development stage: Unknown
Modality: Small Molecules
Administration: Oral

Overview

Xidan (西丹颗粒) is a traditional Chinese medicine (TCM) formulation in granule form. It is currently being studied for its effects on cardiac function, specifically in patients who have undergone percutaneous coronary intervention (PCI) following acute myocardial infarction. The drug is evaluated for its ability to improve left ventricular systolic function and alleviate angina symptoms post-PCI. Its mechanism of action is based on TCM principles and may involve multiple herbal components that act synergistically to promote cardiovascular health, though the precise pharmacological targets are not well defined in Western medical terms[1].

Brand names: 西丹颗粒Xidan
Other names: Xi Dan granules

Beyond the preview

Go deeper on xidan.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on xidan.

Explore the full profile